Stroke Clinical Trials

Find Stroke Clinical Trials Near You

Clinical Characteristics and Stroke Recurrence in Patients With Acute Ischemic Stroke and Active Cancer: The CAT-AIS Multicenter Prospective Observational Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up. The main questions this study aims to answer are: * How often does ischemic stroke recur within 3 months after the initial stroke? * Which clinical factors may be associated with recurrent ischemic stroke? * What other clinical outcomes occur during follow-up? Participants will receive medical care determined by their treating physicians. Researchers will collect information about participants' cancer, stroke characteristics, test results, treatments, recurrent ischemic stroke, and other clinical outcomes. Researchers will also explore whether clinical factors are associated with recurrent ischemic stroke and other outcomes. This study will not assign participants to a specific treatment.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Acute ischemic stroke diagnosed within 7 days after symptom onset or the time last known well.

• Active cancer at the time of the index stroke, as defined below.

Locations
Other Locations
Japan
The Univeristy of Osaka
RECRUITING
Suita
Time Frame
Start Date: 2026-03-01
Estimated Completion Date: 2032-03-31
Participants
Target number of participants: 500
Treatments
Participants with acute ischemic stroke and active cancer
Participants with active cancer who develop acute ischemic stroke and are enrolled prospectively at participating hospitals. Clinical information, treatments, recurrent ischemic stroke, and other outcomes will be collected during follow-up.
Related Therapeutic Areas
Sponsors
Leads: Osaka University

This content was sourced from clinicaltrials.gov